Abiraterone and docetaxel. Medical search. Frequent questions

6. Activity of cabazitaxel in castration-resistant prostate cancer progressing after docetaxel and next-generation endocrine agents. (nih.gov)
7. Cabazitaxel Remains Active in Patients Progressing After Docetaxel Followed by Novel Androgen Receptor Pathway Targeted Therapies. (nih.gov)
11. Efficacy and Safety of Cabazitaxel Versus Abiraterone or Enzalutamide in Older Patients with Metastatic Castration-resistant Prostate Cancer in the CARD Study. (nih.gov)
The chemotherapy agents included cabazitaxel, docetaxel, mitoxantrone hydrochloride, and estramustine, and were used as monotherapy or as combination therapy. (ahdbonline.com)
Dr Higano sought to break up the usual "pathway" chart oncologists often see and get down to basics: there are therapies for mCRPC patients without symptoms (immunotherapy and hormonal therapy, perhaps docetaxel), for those with symptoms (radium 223 is an option), and for those who have had docetaxel (cabazitaxel was listed as the first option). (ajmc.com)
Researchers demonstrate a possible survival advantage by including cabazitaxel in sequences of new agents in the post-docetaxel setting. (renalandurologynews.com)
Based on a study of 344 mCRPC patients treated with at least 2 new agents (abiraterone, enzalutamide, or cabazitaxel) after experiencing disease progression on docetaxel, investigators in Italy led by Orazo Caffo, MD, of Santa Chiara Hospital in Trento, reported that using cabazitaxel in a sequence of new agents offer an advantage in terms of cumulative overall survival. (renalandurologynews.com)
The median overall survival was 11.9 months for patients treated first with a new hormonal agent (abiraterone or enzalutamide) and then with cabazitaxel and 13.4 months for those treated initially with cabazitaxel and then by either abiraterone or enzalutamide. (renalandurologynews.com)
Patients who received abiraterone first followed by enzalutamide, or the reverse sequence, had a median overall survival of 8.3 months, a statistically significantly lower survival compared with the cabazitaxel-containing sequences. (renalandurologynews.com)
and abiraterone or enzalutamide followed by docetaxel and then cabazitaxel (group 3, 41 patients). (renalandurologynews.com)
Efficacy of cabazitaxel, abiraterone, enzalutamide and docetaxel sequence in men with metastatic castration-resistant prostate cancer (mCRPC) in real life practice: The multinational, retrospective, observational CAT study. (renalandurologynews.com)
With this paper, we will review the medical outcomes of several recently approved medicines that extend individual success including cabazitaxel, enzalutamide, abiraterone, sipuleucel-T, and alpharadin (Desk 1). (biopaqc.com)
In the TROPIC (NCT417079) Stage III trial, a complete of 755 CRPC sufferers, who acquired advanced after or during docetaxel-based chemotherapy, had been randomized to get either cabazitaxel or mitoxantrone with both hands receiving dental prednisone [6]. (biopaqc.com)
Predicated on these outcomes, cabazitaxel was accepted by the FDA this year 2010 to take care of docetaxel-refractory-patients with CRPC. (biopaqc.com)
Second-line therapy and therapy for symptomatic CRPC consist of taxane chemotherapy (docetaxel or cabazitaxel), 223 Ra, or AA/enzalutamide (whichever has not been used as the first-line therapy). (snmjournals.org)

The new data prompted Sumanta K. Pal, MD, an American Society of Clinical Oncology (ASCO) expert and urologic oncologist at City of Hope, Duarte, California, and moderator of the GUCS presscast, to think about another drug used in this setting, abiraterone ( Zytiga , Janssen). (medscape.com)
The FDA has granted a priority review to a supplemental New Drug Application (sNDA) for olaparib (Lynparza) for use in combination with abiraterone acetate (Zytiga) and prednisone or prednisolone for the treatment of adult patients with metastatic castration-resistant prostate cancer (mCRPC). (urologytimes.com)
The sNDA is supported by the phase 3 PROpel trial, which showed that adding olaparib (Lynparza) to frontline abiraterone acetate (Zytiga) and prednisone/prednisolone significantly improved radiographic progression-free survival (rPFS) in patients with mCRPC. (urologytimes.com)
Beerse, Belgium, [22nd July 2011] Janssen-Cilag International NV announced today that the Committee for Medical Products for Human Use (CHMP) of the European Medicines Agency (EMA) has granted a positive opinion recommending approval of ZYTIGA ® (abiraterone acetate) under an accelerated regulatory review procedure. (jnj.com)
Abiraterone (Zytiga, Janssen Biotech, Inc. (uspharmacist.com)
We know that men with] mCRPC will experience disease progression on novel hormonal therapies, such as abiraterone acetate (Zytiga) or enzalutamide (Xtandi). (onclive.com)
The results, based on analysis of data from the Cancer Research UK-funded STAMPEDE trial, show that standard hormone therapy combined with another hormone therapy called abiraterone (Zytiga) or a chemotherapy drug called docetaxel give comparable improvements in survival compared to standard hormone therapy alone. (cancerresearchuk.org)

The team reported that docetaxel was estimated to extend predicted survival by an average of 0.89 years for M1 patients and 0.78 years for M0 patients, compared with patients receiving standard of care. (medscape.com)
Cancer Research UK 2019 presents the main findings as: adding docetaxel to hormone therapy improves the length of time men live - this is called overall survival adding abiraterone to hormone therapy improves overall survival and delays the time until the cancer gets worse adding radiotherapy to hormone therapy in men with less prostate cancer spread improves overall survival celecoxib doesn't help men live longer. (wikipedia.org)
11. Matrix metalloproteinase 7, soluble Fas and Fas ligand serum levels for predicting docetaxel resistance and survival in castration-resistant prostate cancer. (nih.gov)
Use of the drug docetaxel with androgen deprivation therapy can improve survival for men with mCSPC. (nih.gov)
5,6 Historically, the treatment of patients with metastatic CRPC was mostly palliative until 2004, when a chemotherapy taxane agent, docetaxel, demonstrated survival benefits. (ahdbonline.com)
Of the 6 therapies with level 1 evidence for survival benefits, only docetaxel itself had been approved "in the last 4 years," she noted. (ajmc.com)
The study demonstrated that abiraterone acetate, in combination with prednisone or prednisolone, improved overall survival (OS) in patients with metastatic castration resistant prostate cancer whose disease had progressed following chemotherapy. (jnj.com)
The prespecified interim analysis was conducted after 552 deaths and showed a statistically significant improvement in overall survival in subjects treated with abiraterone compared to placebo. (uspharmacist.com)
In the interim analysis, the median survival was 14.8 months for the abiraterone arm and 10.9 months for the placebo arm. (uspharmacist.com)
Overall survival (OS) was in the range of 15 months, whether patients received enzalutamide or abiraterone after progression on 1 of the 2 hormonal therapies. (onclive.com)
Newly approved chemotherapeutic agents such as Abiraterone (an oral selective inhibitor of CYP17A), which blocks androgen biosynthesis both within and outside the prostate cancer cells), and enzalutamide (blocks AR signaling) have improved overall survival. (biomedcentral.com)
Overall, there was no significant difference in survival between groups who took abiraterone plus prednisolone or docetaxel. (cancerresearchuk.org)
Combining docetaxel and abiraterone in men who were originally diagnosed with high volume metastases increased overall survival significantly over either alone. (prostatecancer.news)
Radiographic progression-free survival increased by 2.5 years (from 2.0 to 4.5 yrs) with the addition of abiraterone to docetaxel. (prostatecancer.news)
Abiraterone reduced PSA more quickly, as reflected in "failure-free survival" (time to PSA increase, clinical progression, or death) and "progression-free survival" (time to first "failure" event, excluding PSA). (prostatecancer.news)
The other RCTs for metastatic hormone-sensitive prostate cancer (mHSPC) included STAMPEDE- abiraterone, LATITUDE- abiraterone, STAMPEDE-docetaxel, CHAARTED-docetaxel.GETUG-AFU-15(docetaxel) did not detect a difference in survival from the early use of docetaxel. (prostatecancer.news)
The present prospective study aimed to investigate the prevalence of OCT4‑positive (OCT4 + ) CTCs and the potential association with the clinical features and survival of patients with metastatic castration‑resistant prostate cancer (mCRPC) treated with abiraterone + prednisone. (spandidos-publications.com)
Thus, the identification of novel potential biomarkers is required for predicting survival in abiraterone-treated patients with mCRPC. (spandidos-publications.com)
Treatment with the androgen receptor inhibitor darolutamide, in combination with androgen-deprivation therapy (ADT) and docetaxel, significantly improved overall survival (OS) compared with ADT and docetaxel alone in patients with metastatic hormone-sensitive prostate cancer (HSPC), according to recent results from the phase 3 ARASENS clinical trial, which were simultaneously published in the New England Journal of Medicine . (jhoponline.com)
While adding docetaxel to ADT can improve overall survival (OS) and progression-free survival (PFS), chemotherapy increases toxicity, and is not recommended for frail patients. (cancertherapyadvisor.com)
In addition, the use of docetaxel was a major milestone in increasing the overall survival (OS) and clinical response rate in metastatic castration-resistant prostate cancer (mCRPC) [ 2 ]. (e-roj.org)

15. Androgen receptor gene status in plasma DNA associates with worse outcome on enzalutamide or abiraterone for castration-resistant prostate cancer: a multi-institution correlative biomarker study. (nih.gov)

Docetaxel (75 mg/m 2 ) was administered alongside standard of care for six 3-weekly cycles with prednisolone 10 mg daily. (medscape.com)
Standard care plus docetaxel and prednisolone. (wikipedia.org)
SOC plus abiraterone acetate and prednisolone. (wikipedia.org)
SOC plus abiraterone and enzalutamide and prednisolone. (wikipedia.org)
Increased fractures and mortality in combination with radium Ra 223 dichloride: Use of abiraterone acetate plus prednisone/prednisolone in combination with radium Ra 223 dichloride is not recommended. (nih.gov)
The proposed indication is the treatment - with prednisone or prednisolone - of metastatic castration resistant prostate cancer in adult men whose disease has progressed on or after a docetaxel-based chemotherapy regimen. (jnj.com)
In April 2011 abiraterone acetate was approved in the US by the Food and Drug Administration (FDA)for use in combination with prednisone or prednisolone for the treatment of patients with metastatic castration-resistant prostate cancer (CRPC) who have received prior chemotherapy containing docetaxel. (jnj.com)
It includes 566 men who were starting long-term hormone therapy, and were given either abiraterone plus a steroid called prednisolone or docetaxel . (cancerresearchuk.org)
Patients who took abiraterone plus prednisolone or docetaxel alongside hormone therapy survived longer than those taking hormone therapy alone. (cancerresearchuk.org)

Outcomes of metastatic castration-resistant prostate cancer (mCRPC) patients (pts) treated with different new agents (NAs) sequence in post-docetaxel (DOC) setting. (renalandurologynews.com)
RESULTS: A total of 130 patients were included, the majority (n=84, 65%) received radium-223 post docetaxel. (regionh.dk)
Because of this unmet medical need, there's been a tremendous work by both educational and industrial analysts to develop fresh therapeutics that may slow the development of both pre- and post-docetaxel CRPC. (biopaqc.com)

Evaluation of Drug Efficacy), helped establish that docetaxel was an effective option in the treatment of metastatic prostate cancer ( Lancet . (medscape.com)
10. Efficacy of enzalutamide following abiraterone acetate in chemotherapy-naive metastatic castration-resistant prostate cancer patients. (nih.gov)
Updated interim efficacy analysis and longterm safety of abiraterone acetate in metastatic castration-resistant prostate cancer patients without prior chemotherapy (COU-AA-302). (keuzehulp.nl)
antitumor efficacy of all docetaxel-sensitive, -refractory, or -resistant versions, such as for example B16/TXT melanoma [13]. (biopaqc.com)

Abiraterone acetate (AA) is a potent and selective inhibitor of CYP17, which is required for androgen biosynthesis in the testes, adrenal glands, and prostate tissue. (nih.gov)
If approved, Lynparza with abiraterone will become the first combination of a PARP inhibitor and a new hormonal agent for patients with this disease," Susan Galbraith, executive vice president, Oncology R&D, AstraZeneca, the codeveloper of olaparib with MSD (Merck), stated in a press release. (urologytimes.com)

Do not eat food 2 hours before and 1 hour after taking abiraterone acetate tablets. (nih.gov)

In the last decade, the outcome of metastatic prostate cancer has been improved by intensifying the systemic therapy with the addition of docetaxel and/or new hormonal therapies. (buzzsprout.com)

13. Enzalutamide treatment in patients with metastatic castration-resistant prostate cancer progressing after chemotherapy and abiraterone acetate. (nih.gov)
Dr Higano recommended early in course of mCRPC, before second-line hormonal treatments, corticosteroid use with chemotherapy and abiraterone. (ajmc.com)

Emerging clinical data suggests mCRPC patients (pts) treated with anti-androgen therapy like abiraterone (AA) or enzalutamide (ENZA) have decreased responses to susequent therapy with D due to cross-resistance in the androgen pathway targeted by D, AA, and ENZA(van Soest et al, Eur J Cancer 49:18, 2013). (nih.gov)

These patients received either abiraterone orally at a dose of 1,000 mg once daily in combination with prednisone 5 mg orally twice daily or placebo once daily plus prednisone 5 mg orally twice daily. (uspharmacist.com)

Abiraterone is the first-line anti-androgen therapy in patients with mCRPC ( 7 , 8 ). (spandidos-publications.com)

Must have been previously treated with modern anti-androgens such as abiraterone, enzalutamide, apalutamide, or darolutamide. (nih.gov)
Lastly, Dr. Thibault talks about which triplet therapy is recommended to use in clinical practice assuming that abiraterone and darolutamide are both approved in combination with ADT + DOCETAXEL for mHSPC patients. (buzzsprout.com)
ARASENS was a global, randomized, multicenter, double-blind, placebo-controlled clinical trial of 1306 newly diagnosed patients with metastatic HSPC who were randomized (1:1) to oral darolutamide (600 mg twice daily) in combination with ADT and 6 cycles of docetaxel or to placebo, ADT, and docetaxel. (jhoponline.com)
Darolutamide plus ADT and docetaxel reduced the relative risk for death by 32.5% compared with ADT, docetaxel and placebo. (jhoponline.com)

Aggarwal et al presented data from PRESTO (AFT-19) at the European Society for Medical Oncology (ESMO) Congress 2022 (Abstract LBA63), the first trial to evaluate whether intensifying treatment beyond androgen-deprivation therapy (ADT) by adding apalutamide with or without abiraterone acetate plus. (ascopost.com)

CYP3A4 Inducers: Avoid concomitant strong CYP3A4 inducers during abiraterone acetate treatment. (nih.gov)

Adding the chemotherapy docetaxel to standard hormone therapy for both metastatic and nonmetastatic prostate cancer is a win-win-win because it improves patients' overall quality of life (QoL), reduces the need for subsequent therapy, and is cost-effective, according to a new modeling study from the investigators of a major clinical trial. (medscape.com)
The triple benefit (QoL, less need for more therapy, cost-effectiveness) seen in nonmetastatic disease is "somewhat surprising and may cause clinicians to rethink how and when they use docetaxel to treat prostate cancer," he said. (medscape.com)
I will be interesting to assess these results [ie cost and QoL for docetaxel] against recent data for abiraterone, an oral hormonal therapy for prostate cancer, which has similar benefit in the same settings in prostate cancer," he told reporters. (medscape.com)
If you've had a radical prostatectomy , radiation therapy to the area where the prostate was might be an option, sometimes along with hormone therapy (which might include a newer hormone drug such as abiraterone). (cancer.org)
1. The prognostic value of serum MMP-7 levels in prostate cancer patients who received docetaxel, abiraterone, or enzalutamide therapy. (nih.gov)
Six had failed prior docetaxel chemotherapy and one subject had failed prior abiraterone therapy. (pipelinereview.com)
In the LATITUDE trial, we found that abiraterone acetate plus prednisone, in combination with androgen deprivation therapy, demonstrated statistically significant and clinically meaningful improvements in patients with high-risk metastatic hormone-naïve prostate cancer," said Dr. Karim Fizazi, Principal Investigator of the trial and Head of the Medical Oncology Department at Institute Gustave Roussy. (jnj.com)
LATITUDE suggests that abiraterone acetate plus prednisone, in combination with androgen deprivation therapy, can offer a new and much-needed option for patients with high-risk newly diagnosed mHNPC. (jnj.com)
Dr. Thibault answers questions about why triplet therapy (ADT + DOCETAXEL + NHT) is recommended to mHSPC patients, and do all patients benefit from a triplet therapy or only specific subgroups? (buzzsprout.com)
How does this combination therapy compare to previous RCTs for docetaxel or abiraterone? (prostatecancer.news)
Abiraterone acetate plus prednisone and androgen-deprivation therapy (ADT) are linked to improved patient-reported outcomes (PROs) compared with ADT plus placebos among patients with metastatic castration-naive prostate cancer , according to research published in The Lancet Oncology . (cancertherapyadvisor.com)

Moved on to an oncologist that had significant experience treating Prostate CA. He offered a chemical (Abiraterone) to further starve the Prostate of testosterone or a chemotherapeutic called Docetaxel. (cancer.org)
Docetaxel is a standard chemotherapeutic agent traditionally used for castrate-resistant disease. (healthline.com)

Fifty-eight men with progressive metastatic CRPC who experienced treatment failure with docetaxel-based chemotherapy received AA (1,000 mg daily) with prednisone (5 mg twice daily). (nih.gov)
After 2015 SOC was expanded to include docetaxel and radiotherapy (RT) at the start of treatment. (wikipedia.org)
For patients who develop hepatotoxicity during treatment, hold abiraterone acetate tablets until recovery. (nih.gov)
9. Clinical activity and tolerability of enzalutamide (MDV3100) in patients with metastatic, castration-resistant prostate cancer who progress after docetaxel and abiraterone treatment. (nih.gov)
12. Activity of enzalutamide in men with metastatic castration-resistant prostate cancer is affected by prior treatment with abiraterone and/or docetaxel. (nih.gov)
14. Exploring the Clinical Benefit of Docetaxel or Enzalutamide After Disease Progression During Abiraterone Acetate and Prednisone Treatment in Men With Metastatic Castration-Resistant Prostate Cancer. (nih.gov)
6. Circulating-tumor DNA as predictor of enzalutamide response post-abiraterone treatment in metastatic castration-resistant prostate cancer. (nih.gov)
12. AR-V7 in Peripheral Whole Blood of Patients with Castration-resistant Prostate Cancer: Association with Treatment-specific Outcome Under Abiraterone and Enzalutamide. (nih.gov)
To assess the incidence of CNS events in patients with advanced prostate cancer who initiated treatment with abiraterone acetate, bicalutamide, enzalutamide, or chemotherapy. (ahdbonline.com)
The Truven Health MarketScan Research databases were used to retrospectively identify patients with prostate cancer who initiated treatment with abiraterone acetate, enzalutamide, bicalutamide, or chemotherapy after September 1, 2012 (ie, the index date). (ahdbonline.com)
The results of this large observational study suggest that among patients with metasta-tic prostate cancer, treatment with abiraterone acetate is associated with a significantly lower likelihood of having a CNS event compared with treatment with enzalutamide or chemotherapy, but not with bicalu-tamide, even when controlling for metastatic disease. (ahdbonline.com)
We will continue to work closely with the authorities to ensure abiraterone acetate becomes available as quickly as possible to patients who suffer from metastatic castration resistant prostate cancer that has become resistant to conventional hormone therapies and for whom today there are very few treatment options left," commented Jane Griffiths, Company Group Chairman, Janssen Europe, Middle-East, Africa. (jnj.com)
Abiraterone acetate is the first oral, once-daily medication indicated for use in combination with prednisone for the treatment of men with metastatic castration-resistant prostate cancer (CRPC) who have received prior chemotherapy containing docetaxel. (uspharmacist.com)
1. Use of a therapeutically effective amount of abiraterone acetate or a pharmaceutically acceptable salt thereof in the preparation of a medicament for the treatment of a prostate cancer in a human, wherein the medicament is for use with a therapeutically effective amount of prednisone. (gc.ca)
2. Use of a compound for the treatment of a prostate cancer in a human, wherein the compound is a therapeutically effective amount of abiraterone acetate or a pharmaceutically acceptable salt thereof, and is for use with a therapeutically effective amount of prednisone. (gc.ca)
3. Use of a therapeutically effective amount of abiraterone acetate or a pharmaceutically acceptable salt thereof and a therapeutically effective amount of prednisone, for the treatment of a prostate cancer in a human. (gc.ca)
Dr Simon Crabb, a Cancer Research UK-funded prostate cancer expert, said that over the next few months the National Institute for Health and Care Excellent ( NICE ) will be revaluating data to see if abiraterone could be used more widely in prostate cancer patients, which could give them a second treatment option. (cancerresearchuk.org)
In total, 70 patients with mCRPC treated with abiraterone + prednisone were enrolled in the present study and peripheral blood samples were collected prior to treatment initiation to determine CTC count via a Canpatrol system. (spandidos-publications.com)
A prospective study examining elder-relevant outcomes in older adults with prostate cancer undergoing treatment with chemotherapy or abiraterone. (keuzehulp.nl)
Plasma androgen receptor (and genes was evaluated in metastatic CRPC sufferers who received docetaxel-based chemotherapy followed by abiraterone treatment. (ampkpathway.com)
The authors concluded that "treatment with ADT plus abiraterone acetate and prednisone could be considered a new option for standard of care for patients with metastatic castration-naive prostate cancer. (cancertherapyadvisor.com)

SOC plus zoledronic acid and docetaxel. (wikipedia.org)
Are requiring active standard hormone-based therapies (degarelix or leuprolide), antibone resorptive agents (zoledronic acid or denosumab), oral anticancer treatments (abiraterone or second-generation androgen receptor blockers) or intravenous chemotherapy (docetaxel). (mayo.edu)

For the very first time, nowadays there are treatments designed for those individuals who've failed docetaxel. (biopaqc.com)
Currently, the most frequently used first-line treatments for asymptomatic or minimally symptomatic metastatic CRPC are abiraterone acetate (AA) plus prednisone, enzalutamide, or sipuleucel-T (in North America). (snmjournals.org)

This time to CRPC with the triplet has not been reached in median compared with placebo and ADT and docetaxel, as are all of these other parameters" of the secondary end points, Dr Heath noted. (jhoponline.com)

Median rPFS was 33.0 months in the abiraterone acetate plus prednisone with ADT group, compared to 14.8 months with placebo plus ADT. (jnj.com)

Abiraterone in metastatic prostate cancer without previous chemotherapy. (keuzehulp.nl)
Importantly, within this early research a incomplete response was seen in two sufferers with late-stage metastatic prostate cancers, including person who acquired previously been treated with docetaxel. (biopaqc.com)

2. Enzalutamide in castration-resistant prostate cancer patients progressing after docetaxel and abiraterone. (nih.gov)

Dr Higano presented a chart showing standard-of-care options for metastatic castration-resistant prostate cancer (mCRPC), which featured 9 different therapies across columns for patients at various points, from those with symptoms to those without, and for those who have already received docetaxel. (ajmc.com)
Two hormonal therapies, abiraterone and enzalutamide, are also indicated for mCRPC in patients without symptoms. (ajmc.com)

3. Enzalutamide Antitumour Activity Against Metastatic Castration-resistant Prostate Cancer Previously Treated with Docetaxel and Abiraterone: A Multicentre Analysis. (nih.gov)

these rates were 63.4% and 33.6% with placebo/abiraterone, respectively. (urologytimes.com)
In the placebo/abiraterone arm, these rates were 60.6% and 34.1%, respectively. (urologytimes.com)
In the international, double-blind, phase 3 PROpel trial (NCT03732820), investigators randomized patients with mCRPC in the first-line setting 1:1 to receive olaparib at 300 mg twice daily plus abiraterone at 1000 mg daily (n = 399) or placebo and abiraterone at 1000 mg daily (n = 397). (urologytimes.com)
Median OS for the abiraterone acetate plus prednisone in combination with ADT arm was not reached, while the median OS for the placebo plus ADT arm was 34.7 months. (jnj.com)
While abiraterone appears to show less time to chemotherapy than enzalutamide from the placebo arm of the phase 3 study, (8.4 vs 17 months), Dr Higano said it is very important to note that the abiraterone trial included prednisone in the placebo arm, while enzalutamide did not. (ajmc.com)

Patients could have received docetaxel in the metastatic hormone-sensitive prostate cancer (mHSPC) setting, but no prior abiraterone was allowed. (urologytimes.com)
22.5% of patients had received docetaxel at the mHSPC stage. (urologytimes.com)

Abiraterone may have the benefit of improved tolerability over a short course vs chemotherapy but does require a much more extensive duration of use and further mandates concomitant intake of prednisone , a steroid," Dr Pal said. (medscape.com)
Thirty-four of 99 patients with available data (34%) received concomitant abiraterone or enzalutamide. (regionh.dk)

Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. (keuzehulp.nl)
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. (keuzehulp.nl)

This suggests that and copy quantity gain may be useful markers for abiraterone resistance [39]. (ampkpathway.com)
A consistent study found that plasma copy quantity gain was associated with abiraterone resistance in metastatic CRPC individuals [40]. (ampkpathway.com)

Abiraterone acetate tablets 1,000 mg orally once daily with prednisone 5 mg orally twice daily. (nih.gov)

Understanding the cost and quality of life associated with abiraterone may help in selecting either it or docetaxel for these patients with prostate cancer, he summarized. (medscape.com)

Patients receiving abiraterone acetate tablets should also receive a gonadotropin-releasing hormone (GnRH) analog concurrently or should have had bilateral orchiectomy. (nih.gov)
We are encouraged by these positive results for abiraterone acetate in hormone-naïve advanced prostate cancer and are committed to continue developing medicines that can benefit patients at all stages of this serious disease. (jnj.com)
Patients with hormone-sensitive disease where ADT in combination with either docetaxel or abiraterone is indicated will not be eligible (i.e. patients with high burden disease). (bcan.org)

0001). The 1- and 2-year rPFS rates with olaparib plus abiraterone were 73.8% and 53.7%, respectively. (urologytimes.com)

Anatomy1

Diseases14

Chemicals and Drugs32

Analytical, Diagnostic and Therapeutic Techniques and Equipment15

Phenomena and Processes4

Information Science1

Health Care8

Cabazitaxel15

Zytiga7

Survival21

Enzalutamide or abiraterone1

Prednisolone9

Post-docetaxel3

Efficacy4

Inhibitor2

Taking abiraterone acetate1

Addition of docetaxel1

Chemotherapy and abiraterone2

MCRPC patients1

Either abiraterone1

Anti-androgen therapy1

Darolutamide4

Apalutamide1

Acetate treatment1

Therapy11

Chemotherapeutic2

Treatment21

Zoledronic acid2

Treatments2

Triplet1

14.8 months1

Metastatic prostate2

Prostate cancer patients1

Therapies2

Previously treated1

Placebo5

MHSPC2

Concomitant2

Mitoxantrone2

Resistance2

1,000 mg1

Patients with prostate cancer1

Hormone3

RPFS1